Why these top ASX 200 growth shares could rise 35%+ in 2025

Analysts are tipping these shares to deliver big returns for investors over the next 12 months.

| More on:
A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are you a fan of growth stocks? If you are, then it could be worth looking at the two ASX 200 growth shares listed below.

That's because they have been named as buys by brokers and tipped to rise strongly from current levels.

Here's what they are saying about them:

Neuren Pharmaceuticals Ltd (ASX: NEU)

The first ASX 200 growth share that could have major upside potential according to analysts is Neuren Pharmaceuticals.

It is a pharmaceuticals company that is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.

The company notes that all programs have been granted orphan drug designation in the United States. This designation provides incentives to encourage development of therapies for rare and serious diseases.

Bell Potter is feeling positive about the company's outlook. Especially given the potential of its NNZ-2591 product candidate, which is being trialled in children with Angelman syndrome. It explains:

We have updated our near-term forecasts to reflect the PRV sale timing and the assumption that NEU will internally fund multiple Phase 3 trials for NNZ-2591 over the next few years. Our BUY recommendation and $25.00 PT remains unchanged.

Roughly $10/share of our valuation is attributed to Daybue licensing income, hence our BUY recommendation is driven by a positive view on NNZ-2591. The next steps for NNZ-2591 are further FDA engagement on the Phase 3 design in PhelanMcDermid syndrome, likely in 1Q CY25, followed by starting the Phase 3 trial in CY25.

Bell Potter has a buy rating and $25.00 price target on its shares. This implies potential upside of over 100% for investors.

Nextdc Ltd (ASX: NXT)

Another ASX 200 growth share that could generate big returns according to analysts is NextDC.

It is a leading provider of innovative data centre outsourcing solutions, connectivity services, and infrastructure management software.

Morgans is a big fan of the company and believes it will benefit greatly from the artificial intelligence (AI) megatrend. It said:

Enjoying all the benefits of the AI growth opportunity with less volatility are the operators of data centres. Data centres are facilities that store, process, and manage the vast amounts of data foundational to AI, ensuring secure and efficient data flow, backup, and recovery. […] Digital Realty recently reported a record sales quarter during which it sold double the data centre capacity of its previous high and about four times more capacity than it usually sells in a quarter.

This reinforces our view that the significant demand for cloud computing and AI-related digital infrastructure is going to unpin attractive returns and long-term growth. […] Our preferred exposure is NEXTDC. It has 17 operational data centres in Australia and nearly a dozen under construction or about to be built across Australasia and Asia.

Morgans currently has an add rating and $20.50 price target on its shares. This suggests that upside of 37% is possible for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in Nextdc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Two excited woman pointing out a bargain opportunity on a laptop.
Growth Shares

2 ASX growth shares with rapidly-rising dividends to buy now

Rapidly growing businesses are appealing for multiple reasons.

Read more »

a man in a green and gold Australian athletic kit roars ecstatically with a wide open mouth while his hands are clenched and raised as a shower of gold confetti falls in the sky around him.
Growth Shares

3 amazing Australian stocks to buy and hold until 2030

Analysts think these shares could be high-quality options for investors looking for long term picks.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Growth Shares

Why these ASX 200 growth shares could rise 40% in 12 months

Analysts are tipping these shares to deliver big returns over the next 12 months.

Read more »

A woman makes the task of vacuuming fun, leaping while she pretends it is an air guitar.
Opinions

Opinion: This is one of the best ASX growth shares to own for the next 5 years

This stock is rapidly growing, and I’m excited about it.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Growth Shares

Buy Xero and this ASX 200 growth share in February

Analysts have good things to say about these growing companies.

Read more »

happy investor, share price rise, increase, up
Growth Shares

Buy these ASX growth shares with $3,000 in February

Analysts think these growth shares could be great options for investors with money to put into the share market.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Growth Shares

2 no-brainer ASX All Ords shares to buy with $2,000

Analysts have good things to say about these stocks. Let's see why they are so bullish.

Read more »

Two men look excited on the trading floor as they hold telephones to their ears and one points upwards.
Growth Shares

Where to invest $1,000 into ASX 200 stocks in February

Analysts think these shares would be great options for Aussie investors next month.

Read more »